These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 25486101)

  • 1. Dopamine heteroreceptor complexes as therapeutic targets in Parkinson's disease.
    Fuxe K; Guidolin D; Agnati LF; Borroto-Escuela DO
    Expert Opin Ther Targets; 2015 Mar; 19(3):377-98. PubMed ID: 25486101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adenosine heteroreceptor complexes in the basal ganglia are implicated in Parkinson's disease and its treatment.
    Borroto-Escuela DO; Fuxe K
    J Neural Transm (Vienna); 2019 Apr; 126(4):455-471. PubMed ID: 30637481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. L-DOPA treatment selectively restores spine density in dopamine receptor D2-expressing projection neurons in dyskinetic mice.
    Suárez LM; Solís O; Caramés JM; Taravini IR; Solís JM; Murer MG; Moratalla R
    Biol Psychiatry; 2014 May; 75(9):711-22. PubMed ID: 23769604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the dopamine D3 receptor: an overview of drug design strategies.
    Cortés A; Moreno E; Rodríguez-Ruiz M; Canela EI; Casadó V
    Expert Opin Drug Discov; 2016 Jul; 11(7):641-64. PubMed ID: 27135354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brain Dopamine Transmission in Health and Parkinson's Disease: Modulation of Synaptic Transmission and Plasticity Through Volume Transmission and Dopamine Heteroreceptors.
    Borroto-Escuela DO; Perez De La Mora M; Manger P; Narváez M; Beggiato S; Crespo-Ramírez M; Navarro G; Wydra K; Díaz-Cabiale Z; Rivera A; Ferraro L; Tanganelli S; Filip M; Franco R; Fuxe K
    Front Synaptic Neurosci; 2018; 10():20. PubMed ID: 30042672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enkephalin and dynorphin neuropeptides are differently correlated with locomotor hypersensitivity and levodopa-induced dyskinesia in parkinsonian rats.
    Sgroi S; Capper-Loup C; Paganetti P; Kaelin-Lang A
    Exp Neurol; 2016 Jun; 280():80-8. PubMed ID: 27072528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of synaptic D1 dopamine/N-methyl-D-aspartate glutamate receptor complexes in L-DOPA-induced dyskinesia in the rat.
    Fiorentini C; Rizzetti MC; Busi C; Bontempi S; Collo G; Spano P; Missale C
    Mol Pharmacol; 2006 Mar; 69(3):805-12. PubMed ID: 16365282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of receptor heterodimers in the development of L-dopa-induced dyskinesias in the 6-hydroxydopamine rat model of Parkinson's disease.
    Fiorentini C; Busi C; Spano P; Missale C
    Parkinsonism Relat Disord; 2008; 14 Suppl 2():S159-64. PubMed ID: 18638717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The differential effects of 5-HT(1A) receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rat.
    Dupre KB; Eskow KL; Negron G; Bishop C
    Brain Res; 2007 Jul; 1158():135-43. PubMed ID: 17553470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistent activation of the D1R/Shp-2/Erk1/2 pathway in l-DOPA-induced dyskinesia in the 6-hydroxy-dopamine rat model of Parkinson's disease.
    Fiorentini C; Savoia P; Savoldi D; Barbon A; Missale C
    Neurobiol Dis; 2013 Jun; 54():339-48. PubMed ID: 23328768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].
    Damier P; Tremblay L; Féger J; Hirsch EC
    Rev Neurol (Paris); 2000 Mar; 156(3):224-35. PubMed ID: 10740093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding the Role of GPCR Heteroreceptor Complexes in Modulating the Brain Networks in Health and Disease.
    Borroto-Escuela DO; Carlsson J; Ambrogini P; Narváez M; Wydra K; Tarakanov AO; Li X; Millón C; Ferraro L; Cuppini R; Tanganelli S; Liu F; Filip M; Diaz-Cabiale Z; Fuxe K
    Front Cell Neurosci; 2017; 11():37. PubMed ID: 28270751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic exposure to dopamine agonists affects the integrity of striatal D
    Politis M; Wilson H; Wu K; Brooks DJ; Piccini P
    Neuroimage Clin; 2017; 16():455-460. PubMed ID: 28879087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopamine receptor dysregulation in hippocampus of aged rats underlies chronic pulsatile L-Dopa treatment induced cognitive and emotional alterations.
    Hernández VS; Luquín S; Jáuregui-Huerta F; Corona-Morales AA; Medina MP; Ruíz-Velasco S; Zhang L
    Neuropharmacology; 2014 Jul; 82():88-100. PubMed ID: 24291463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The 'magic' of L-dopa: why is it the gold standard Parkinson's disease therapy?
    Mercuri NB; Bernardi G
    Trends Pharmacol Sci; 2005 Jul; 26(7):341-4. PubMed ID: 15936832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential effects of the NMDA receptor antagonist MK-801 on dopamine receptor D1- and D2-induced abnormal involuntary movements in a preclinical model.
    Flores AJ; Bartlett MJ; So LY; Laude ND; Parent KL; Heien ML; Sherman SJ; Falk T
    Neurosci Lett; 2014 Apr; 564():48-52. PubMed ID: 24525249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apomorphine continuous stimulation in Parkinson's disease: receptor desensitization as a possible mechanism of reduced motor response.
    Maggio R; Barbier P; Corsini GU
    J Neural Transm Suppl; 1995; 45():133-6. PubMed ID: 8748618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peculiarities of L: -DOPA treatment of Parkinson's disease.
    Kostrzewa RM; Nowak P; Kostrzewa JP; Kostrzewa RA; Brus R
    Amino Acids; 2005 Mar; 28(2):157-64. PubMed ID: 15750845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective activation of striatal indirect pathway suppresses levodopa induced-dyskinesias.
    Castela I; Casado-Polanco R; Rubio YV; da Silva JA; Marquez R; Pro B; Moratalla R; Redgrave P; Costa RM; Obeso J; Hernandez LF
    Neurobiol Dis; 2023 Jan; 176():105930. PubMed ID: 36414182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopamine D2 heteroreceptor complexes and their receptor-receptor interactions in ventral striatum: novel targets for antipsychotic drugs.
    Fuxe K; Borroto-Escuela DO; Tarakanov AO; Romero-Fernandez W; Ferraro L; Tanganelli S; Perez-Alea M; Di Palma M; Agnati LF
    Prog Brain Res; 2014; 211():113-39. PubMed ID: 24968778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.